Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLand & ImprovementsLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Total Liabilities (2016 - 2025)

Abvc Biopharma (ABVC) has disclosed Total Liabilities for 13 consecutive years, with $7.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Total Liabilities rose 13.92% year-over-year to $7.8 million, compared with a TTM value of $7.8 million through Dec 2025, up 13.92%, and an annual FY2025 reading of $7.8 million, up 13.92% over the prior year.
  • Total Liabilities was $7.8 million for Q4 2025 at Abvc Biopharma, up from $6.7 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $9.7 million in Q2 2023 and bottomed at $4.6 million in Q2 2022.
  • Average Total Liabilities over 5 years is $6.7 million, with a median of $6.6 million recorded in 2023.
  • The sharpest move saw Total Liabilities soared 650.46% in 2021, then tumbled 46.51% in 2022.
  • Year by year, Total Liabilities stood at $4.8 million in 2021, then soared by 31.4% to $6.3 million in 2022, then rose by 2.96% to $6.5 million in 2023, then grew by 4.36% to $6.8 million in 2024, then rose by 13.92% to $7.8 million in 2025.
  • Business Quant data shows Total Liabilities for ABVC at $7.8 million in Q4 2025, $6.7 million in Q3 2025, and $6.8 million in Q2 2025.